![]() ![]() ( 1) found reduced induction of neutralizing antibodies from BNT62b2. Currently, there is concern about reduced vaccine-induced immune protection to emerging variants that have mutations in the spike protein. The 95% efficacy of the BNT162b2 messenger RNA (mRNA) vaccine (from Pfizer/BioNTech) heralded a series of results showing that eliciting neutralizing antibodies to spike strongly correlated with protection from disease in clinical trials of various vaccines. All the vaccines aim to prevent disease primarily (but not exclusively) by eliciting neutralizing antibodies that block spike and therefore prevent the ability of SARS-CoV-2 to infect cells. Vaccine candidates based on spike, the glycoprotein that is essential for host cell entry by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), were being designed within days of its reported sequence in January 2020.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |